AcouSort secures technology rights from DTU

AcouSort AB (“AcouSort”) has signed an agreement obtaining the rights to acquire an invention from the Technical University of Denmark (“DTU”). The invention relates to technology developed by Professor Henrik Bruus at DTU in collaboration with AcouSort and concerns a new and more efficient way of manufacturing AcouSort’s acoustic chip.

“With this new technology, the future AcouSort separation chips will be easier to manufacture at high volumes in a more cost-effective way. By signing this agreement, we ensure that AcouSort stays in the absolute front line of developing acoustofluidics for automated sample preparation,” says AcouSort’s CEO Torsten Freltoft.

The development was made within the EU project BioWings, where AcouSort and DTU together with several other companies and universities are working on the development of the next generation of ultrasonic chips. AcouSort has already filed a patent application based on the invention. This is the second patent application that AcouSort’s long and successful collaboration with DTU has resulted in. The first acquisition of patent rights from DTU was announced in a press release on 19 January 2018.

For further information on AcouSort, please contact:

Torsten Freltoft, CEO

Telephone: +45 2045 0854

E-mail: torsten.freltoft@acousort.com

About AcouSort

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company’s products can separate blood cells, concentrate, purify and stain cells, exosomes and bacteria from biological samples. The technology of the company’s products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company’s commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company’s research instruments. With the help of the company’s products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases and cardiovascular diseases.